WithdrawnNot Applicable

Analyses of Exosomes in the Cerebrospinal Fluid for Breast Cancer Patients With Suspicion of Leptomeningeal Metastasis.

Stopped: Modification of the care habits. We believe today that we are no longer able to carry out this study as initially described.

France0Started 2019-07

Plain-language summary

This is a multicenter, interventional, prospective study among breast cancer patients with a suspicion of metastatic meningitis. The current study aims to assess the use of proteomic profile issued from cerebrospinal fluid microvesicles for diagnosis of leptomeningeal metastases.

Who can participate

Age range18 Years

SexFEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patient with histologically proven breast cancer * Patient with suspected metastatic leptomeningitis * Age ≥ 18 years * Patient covered by the French social security regime * Signed written informed consent Exclusion Criteria: * History of cancer other than the one being treated * Contraindication to carrying out the lumbar puncture or cerebrospinal MRI * Pregnant or breastfeeding patient

What they're measuring

Proteomic profiles issued from cerebrospinal fluid at diagnosis

Timeframe: Up to 1 week

Cytology of cerebrospinal fluid at diagnosis

Timeframe: Up to 1 week

Trial details

NCT IDNCT03974204

SponsorCentre Oscar Lambret

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2022-10

View on ClinicalTrials.gov More Breast Cancer trials